Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether there were differences in clinical characteristics, response, and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hemasphere
Main Authors: Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.
Formato: Artigo
Idioma:Inglês
Publicado: Wolters Kluwer Health 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306303/
https://ncbi.nlm.nih.gov/pubmed/32647793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000363
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares